Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without

You may also be interested in...

Sanofi Cuts Development Of 14 Drugs In First Quarter, With More R&D Changes To Come

Among halted development programs is Phase III antidepressant saredutant; decision on Plavix follow-on idrabiotaparinux awaits FDA safety determination.

With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too

With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has

Pfizer’s IGF-1 Inhibitor Leads Pack In Phase III For NSCLC

Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts